Compare Gilead Sciences, Inc. (GILD) vs Zoetis Inc (ZTS) Price & Performance

Gilead Sciences (GILD) trades at $130.04, down 1.04% on the day, with technical indicators showing a bearish bias while fundamentals remain strong. The company has beaten earnings expectations for three consecutive quarters, maintains robust profitability with a 30.99% net income margin, and recently secured FDA and European Commission approvals for expanded use of its oncology drug Trodelvy. Analyst consensus remains overwhelmingly positive with a $152.83 price target representing 17.5% upside potential.

The outlook for GILD is favorable with strong earnings momentum, expanding oncology portfolio, and solid cash generation, though risks include patent expirations, competitive pressures in HIV treatments, and recent negative cash flow trends. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharmaceutical company with growth catalysts, supported by Wall Street's bullish sentiment and recent regulatory wins.

ZTS trades at $74.08, down 1.74% on the day, with a bearish technical signal from moving averages. The company reported strong 2025 results including $9.47B revenue, $2.67B net income, and a 28.03% net margin, but missed Q1 2026 EPS estimates. Recent news highlights a securities class action lawsuit and the launch of Lenivia in Canada and the EU.

Despite near-term legal overhangs and a recent earnings miss, ZTS maintains robust profitability and a consensus price target of $101.43 implies significant upside. Key risks include litigation outcomes and competitive pressures in the companion animal segment, while solid cash flow and high ROE support long-term value.